Answer
Madopar CR is indicated to treat all stages of Parkinson’s disease, with patients experiencing fluctuations related to levodopa plasma concentrations or dose timing, such as wearing-off effects, more likely to benefit from switching to it.
Sources for this answer
- Madopar CR 100 mg/25 mg Prolonged Release Hard CapsulesRoche Products Limited · emc · SmPC §4.1 Therapeutic Indications · Version 18Document updated
Sources checked